Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Industry sources reveal drug companies have stopped negotiating listings on the PBS and in some cases are considering not ...

Pfizer Inc. (NYSE: PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug ...

Pfizer and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...